Plaque2.0-A High-Throughput Analysis Framework to Score Virus-Cell Transmission and Clonal Cell Expansion

PLoS One. 2015 Sep 28;10(9):e0138760. doi: 10.1371/journal.pone.0138760. eCollection 2015.

Abstract

Classical plaque assay measures the propagation of infectious agents across a monolayer of cells. It is dependent on cell lysis, and limited by user-specific settings and low throughput. Here, we developed Plaque2.0, a broadly applicable, fluorescence microscopy-based high-throughput method to mine patho-biological clonal cell features. Plaque2.0 is an open source framework to extract information from chemically fixed cells by immuno-histochemistry or RNA in situ hybridization, or from live cells expressing GFP transgene. Multi-parametric measurements include infection density, intensity, area, shape or location information at single plaque or population levels. Plaque2.0 distinguishes lytic and non-lytic spread of a variety of DNA and RNA viruses, including vaccinia virus, adenovirus and rhinovirus, and can be used to visualize simultaneous plaque formation from co-infecting viruses. Plaque2.0 also analyzes clonal growth of cancer cells, which is relevant for cell migration and metastatic invasion studies. Plaque2.0 is suitable to quantitatively analyze virus infections, vector properties, or cancer cell phenotypes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / physiology
  • Animals
  • Cell Count
  • Cell Line
  • Cell Proliferation
  • Clone Cells
  • Coculture Techniques
  • Genotype
  • High-Throughput Screening Assays / methods*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Microscopy, Fluorescence
  • Neoplasms / pathology
  • Phenotype
  • Picornaviridae Infections / virology
  • Rhinovirus / genetics
  • Software*
  • Time-Lapse Imaging
  • Vaccinia virus
  • Viral Plaque Assay / methods*
  • Viruses / metabolism*

Grants and funding

Funding was obtained from the Swiss National Science Foundation (31003A_141222/1 and 310030B_160316 to UFG), the Medical Research and Development project VirX from SystemsX.ch (to UFG), the Novartis Foundation, and the Kanton Zurich. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.